Recombinant Isfahan virus and vesicular stomatitis virus vaccine vectors provide durable, multivalent, single-dose protection against lethal alphavirus challenge

Farooq Nasar, Demetrius Matassov, Robert Seymour, Theresa Latham, Rodion V. Gorchakov, Rebecca M. Nowak, Grace Leal, Stefan Hamm, John H. Eldridge, Robert B. Tesh, David K. Clarke, Scott Weaver

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The demonstrated clinical efficacy of a recombinant vesicular stomatitis virus (rVSV) vaccine vector has stimulated the investigation of additional serologically distinct Vesiculovirus vectors as therapeutic and/or prophylactic vaccine vectors to combat emerging viral diseases. Among these viral threats are the encephalitic alphaviruses Venezuelan equine encephalitis virus (VEEV) and Eastern equine encephalitis virus (EEEV), which have demonstrated potential for natural disease outbreaks, yet no licensed vaccines are available in the event of an epidemic. Here we report the rescue of recombinant Isfahan virus (rISFV) from genomic cDNA as a potential new vaccine vector platform. The rISFV genome was modified to attenuate virulence and express the VEEV and EEEV E2/E1 surface glycoproteins as vaccine antigens. A single dose of the rISFV vaccine vectors elicited neutralizing antibody responses and protected mice from lethal VEEV and EEEV challenges at 1 month postvaccination as well as lethal VEEV challenge at 8 months postvaccination. A mixture of rISFV vectors expressing the VEEV and EEEV E2/E1 glycoproteins also provided durable, single-dose protection from lethal VEEV and EEEV challenges, demonstrating the potential for a multivalent vaccine formulation. These findings were paralleled in studies with an attenuated form of rVSV expressing the VEEV E2/E1 glycoproteins. Both the rVSV and rISFV vectors were attenuated by using an approach that has demonstrated safety in human trials of an rVSV/HIV-1 vaccine. Vaccines based on either of these vaccine vector platforms may present a safe and effective approach to prevent alphavirus-induced disease in humans.

Original languageEnglish (US)
Article numbere01729-16
JournalJournal of Virology
Volume91
Issue number8
DOIs
StatePublished - Apr 1 2017

Fingerprint

Isfahan virus
Venezuelan equine encephalitis virus
Alphavirus
Vesiculovirus
vector vaccines
Vesicular Stomatitis
Venezuelan Equine Encephalitis Viruses
Eastern equine encephalitis virus
lethal genes
Vaccines
Viruses
dosage
vaccines
glycoproteins
Glycoproteins
Human immunodeficiency virus 1
neutralizing antibodies
AIDS Vaccines
human diseases
Membrane Glycoproteins

Keywords

  • Eastern equine encephalitis virus
  • Isfahan virus
  • Venezuelan equine encephalitis virus
  • Vesicular stomatitis virus

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Recombinant Isfahan virus and vesicular stomatitis virus vaccine vectors provide durable, multivalent, single-dose protection against lethal alphavirus challenge. / Nasar, Farooq; Matassov, Demetrius; Seymour, Robert; Latham, Theresa; Gorchakov, Rodion V.; Nowak, Rebecca M.; Leal, Grace; Hamm, Stefan; Eldridge, John H.; Tesh, Robert B.; Clarke, David K.; Weaver, Scott.

In: Journal of Virology, Vol. 91, No. 8, e01729-16, 01.04.2017.

Research output: Contribution to journalArticle

Nasar, Farooq ; Matassov, Demetrius ; Seymour, Robert ; Latham, Theresa ; Gorchakov, Rodion V. ; Nowak, Rebecca M. ; Leal, Grace ; Hamm, Stefan ; Eldridge, John H. ; Tesh, Robert B. ; Clarke, David K. ; Weaver, Scott. / Recombinant Isfahan virus and vesicular stomatitis virus vaccine vectors provide durable, multivalent, single-dose protection against lethal alphavirus challenge. In: Journal of Virology. 2017 ; Vol. 91, No. 8.
@article{6f7ecd028846474d93cc06e593a04ff6,
title = "Recombinant Isfahan virus and vesicular stomatitis virus vaccine vectors provide durable, multivalent, single-dose protection against lethal alphavirus challenge",
abstract = "The demonstrated clinical efficacy of a recombinant vesicular stomatitis virus (rVSV) vaccine vector has stimulated the investigation of additional serologically distinct Vesiculovirus vectors as therapeutic and/or prophylactic vaccine vectors to combat emerging viral diseases. Among these viral threats are the encephalitic alphaviruses Venezuelan equine encephalitis virus (VEEV) and Eastern equine encephalitis virus (EEEV), which have demonstrated potential for natural disease outbreaks, yet no licensed vaccines are available in the event of an epidemic. Here we report the rescue of recombinant Isfahan virus (rISFV) from genomic cDNA as a potential new vaccine vector platform. The rISFV genome was modified to attenuate virulence and express the VEEV and EEEV E2/E1 surface glycoproteins as vaccine antigens. A single dose of the rISFV vaccine vectors elicited neutralizing antibody responses and protected mice from lethal VEEV and EEEV challenges at 1 month postvaccination as well as lethal VEEV challenge at 8 months postvaccination. A mixture of rISFV vectors expressing the VEEV and EEEV E2/E1 glycoproteins also provided durable, single-dose protection from lethal VEEV and EEEV challenges, demonstrating the potential for a multivalent vaccine formulation. These findings were paralleled in studies with an attenuated form of rVSV expressing the VEEV E2/E1 glycoproteins. Both the rVSV and rISFV vectors were attenuated by using an approach that has demonstrated safety in human trials of an rVSV/HIV-1 vaccine. Vaccines based on either of these vaccine vector platforms may present a safe and effective approach to prevent alphavirus-induced disease in humans.",
keywords = "Eastern equine encephalitis virus, Isfahan virus, Venezuelan equine encephalitis virus, Vesicular stomatitis virus",
author = "Farooq Nasar and Demetrius Matassov and Robert Seymour and Theresa Latham and Gorchakov, {Rodion V.} and Nowak, {Rebecca M.} and Grace Leal and Stefan Hamm and Eldridge, {John H.} and Tesh, {Robert B.} and Clarke, {David K.} and Scott Weaver",
year = "2017",
month = "4",
day = "1",
doi = "10.1128/JVI.01729-16",
language = "English (US)",
volume = "91",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Recombinant Isfahan virus and vesicular stomatitis virus vaccine vectors provide durable, multivalent, single-dose protection against lethal alphavirus challenge

AU - Nasar, Farooq

AU - Matassov, Demetrius

AU - Seymour, Robert

AU - Latham, Theresa

AU - Gorchakov, Rodion V.

AU - Nowak, Rebecca M.

AU - Leal, Grace

AU - Hamm, Stefan

AU - Eldridge, John H.

AU - Tesh, Robert B.

AU - Clarke, David K.

AU - Weaver, Scott

PY - 2017/4/1

Y1 - 2017/4/1

N2 - The demonstrated clinical efficacy of a recombinant vesicular stomatitis virus (rVSV) vaccine vector has stimulated the investigation of additional serologically distinct Vesiculovirus vectors as therapeutic and/or prophylactic vaccine vectors to combat emerging viral diseases. Among these viral threats are the encephalitic alphaviruses Venezuelan equine encephalitis virus (VEEV) and Eastern equine encephalitis virus (EEEV), which have demonstrated potential for natural disease outbreaks, yet no licensed vaccines are available in the event of an epidemic. Here we report the rescue of recombinant Isfahan virus (rISFV) from genomic cDNA as a potential new vaccine vector platform. The rISFV genome was modified to attenuate virulence and express the VEEV and EEEV E2/E1 surface glycoproteins as vaccine antigens. A single dose of the rISFV vaccine vectors elicited neutralizing antibody responses and protected mice from lethal VEEV and EEEV challenges at 1 month postvaccination as well as lethal VEEV challenge at 8 months postvaccination. A mixture of rISFV vectors expressing the VEEV and EEEV E2/E1 glycoproteins also provided durable, single-dose protection from lethal VEEV and EEEV challenges, demonstrating the potential for a multivalent vaccine formulation. These findings were paralleled in studies with an attenuated form of rVSV expressing the VEEV E2/E1 glycoproteins. Both the rVSV and rISFV vectors were attenuated by using an approach that has demonstrated safety in human trials of an rVSV/HIV-1 vaccine. Vaccines based on either of these vaccine vector platforms may present a safe and effective approach to prevent alphavirus-induced disease in humans.

AB - The demonstrated clinical efficacy of a recombinant vesicular stomatitis virus (rVSV) vaccine vector has stimulated the investigation of additional serologically distinct Vesiculovirus vectors as therapeutic and/or prophylactic vaccine vectors to combat emerging viral diseases. Among these viral threats are the encephalitic alphaviruses Venezuelan equine encephalitis virus (VEEV) and Eastern equine encephalitis virus (EEEV), which have demonstrated potential for natural disease outbreaks, yet no licensed vaccines are available in the event of an epidemic. Here we report the rescue of recombinant Isfahan virus (rISFV) from genomic cDNA as a potential new vaccine vector platform. The rISFV genome was modified to attenuate virulence and express the VEEV and EEEV E2/E1 surface glycoproteins as vaccine antigens. A single dose of the rISFV vaccine vectors elicited neutralizing antibody responses and protected mice from lethal VEEV and EEEV challenges at 1 month postvaccination as well as lethal VEEV challenge at 8 months postvaccination. A mixture of rISFV vectors expressing the VEEV and EEEV E2/E1 glycoproteins also provided durable, single-dose protection from lethal VEEV and EEEV challenges, demonstrating the potential for a multivalent vaccine formulation. These findings were paralleled in studies with an attenuated form of rVSV expressing the VEEV E2/E1 glycoproteins. Both the rVSV and rISFV vectors were attenuated by using an approach that has demonstrated safety in human trials of an rVSV/HIV-1 vaccine. Vaccines based on either of these vaccine vector platforms may present a safe and effective approach to prevent alphavirus-induced disease in humans.

KW - Eastern equine encephalitis virus

KW - Isfahan virus

KW - Venezuelan equine encephalitis virus

KW - Vesicular stomatitis virus

UR - http://www.scopus.com/inward/record.url?scp=85016640124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016640124&partnerID=8YFLogxK

U2 - 10.1128/JVI.01729-16

DO - 10.1128/JVI.01729-16

M3 - Article

C2 - 28148802

AN - SCOPUS:85016640124

VL - 91

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 8

M1 - e01729-16

ER -